UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
DUBLIN, Ireland, March 05, 2018 --
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2017 on Wednesday, March 7, 2018. The Company has scheduled a conference call for that same day, Wednesday, March 7, 2018 at 11:00 am ET (4:00 pm GMT) to discuss the results of the quarter.
| Interested parties can access the call by dialing: | ||
| USA: | 1-844-861-5499 | |
| International: | 1-412-317-6581 | |
| Conference ID #: | 10117673 | |
A simultaneous webcast of the call can be accessed at:
https://www.webcaster4.com/Webcast/Page/1135/24877
| A replay of the call can be accessed until March 14, 2018 by dialing: | ||
| USA: | 1-877-344-7529 | |
| International: | 1-412-317-0088 | |
| Conference ID #: | 10117673 | |
The webcast of the call will be available for 30 days at:
https://www.webcaster4.com/Webcast/Page/1135/24877
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
Contact
Kevin Tansley
Trinity Biotech plc
(353)-1-2769800
E-mail: [email protected]
Joe Diaz, Joe Dorame and Robert Blum
Lytham Partners, LLC
Investor Relations
602-889-9700
